148 related articles for article (PubMed ID: 32695960)
1. Risk factors of hyperprolactinemia induced by risperidone and olanzapine and their correlations with plasma glucose and lipids.
He S; Yu WJ; Wang X; Zhang L; Zhao N; Li G; Shen YF; Li H
Gen Psychiatr; 2020; 33(4):e100206. PubMed ID: 32695960
[TBL] [Abstract][Full Text] [Related]
2. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Schizophr Res; 2013 Apr; 145(1-3):116-9. PubMed ID: 23375624
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
4. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
[TBL] [Abstract][Full Text] [Related]
5. Integrating machine learning with electronic health record data to facilitate detection of prolactin level and pharmacovigilance signals in olanzapine-treated patients.
Zhu X; Hu J; Xiao T; Huang S; Shang D; Wen Y
Front Endocrinol (Lausanne); 2022; 13():1011492. PubMed ID: 36313772
[TBL] [Abstract][Full Text] [Related]
6. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
Yoshimura Y; Takeda T; Kishi Y; Harada T; Nomura A; Washida K; Yoshimura B; Sato K; Yada Y; Aoki S
J Clin Psychopharmacol; 2017 Jun; 37(3):296-301. PubMed ID: 28306616
[TBL] [Abstract][Full Text] [Related]
7. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
[TBL] [Abstract][Full Text] [Related]
9. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.
Hatta K; Otachi T; Sudo Y; Kuga H; Takebayashi H; Hayashi H; Ishii R; Kasuya M; Hayakawa T; Morikawa F; Hata K; Nakamura M; Usui C; Nakamura H; Hirata T; Sawa Y;
Psychiatry Res; 2012 Jul; 198(2):194-201. PubMed ID: 22421064
[TBL] [Abstract][Full Text] [Related]
10. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
David SR; Taylor CC; Kinon BJ; Breier A
Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
[TBL] [Abstract][Full Text] [Related]
11. [Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].
Sacristán JA; Gómez JC; Ferre F; Gascón J; Pérez Bravo A; Olivares JM
Actas Esp Psiquiatr; 2001; 29(1):25-32. PubMed ID: 11333516
[TBL] [Abstract][Full Text] [Related]
12. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Melkersson K; Berinder K; Hulting AL
Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.
Hatta K; Kawabata T; Yoshida K; Hamakawa H; Wakejima T; Furuta K; Nakamura M; Hirata T; Usui C; Nakamura H; Sawa Y
Gen Hosp Psychiatry; 2008; 30(4):367-71. PubMed ID: 18585542
[TBL] [Abstract][Full Text] [Related]
14. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.
Lambert M; Conus P; Schimmelmann BG; Eide P; Ward J; Yuen H; Schacht M; Edwards J; Naber D; McGorry PD
Pharmacopsychiatry; 2005 Sep; 38(5):206-13. PubMed ID: 16189747
[TBL] [Abstract][Full Text] [Related]
15. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.
Suzuki Y; Sugai T; Ono S; Sawamura K; Fukui N; Watanabe J; Tsuneyama N; Saito M; Someya T
Psychiatry Clin Neurosci; 2014 May; 68(5):353-6. PubMed ID: 24405493
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
[TBL] [Abstract][Full Text] [Related]
18. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Crawford AM; Beasley CM; Tollefson GD
Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
[TBL] [Abstract][Full Text] [Related]
19. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.
Melkersson K
J Clin Psychiatry; 2005 Jun; 66(6):761-7. PubMed ID: 15960571
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
